Whitfield Advises GTCR-Backed Corza Medical on Divestiture of Biosurgery Business Unit to EQT
Overview
GTCR-backed Corza Medical agreed to sell its Biosurgery division to EQT, according to the source announcement about the medical-technology business.
Product perimeter
The divestiture included the TachoSil product portfolio. The statement concerns a business unit rather than the whole Corza group.
Timing and disclosure
Closing was anticipated in the fourth quarter of 2026 following regulatory approvals and other conditions. The price was not disclosed.
Named advisers
Christopher Thomas, Kyle McHugh, Jacob Traff and Andrew McAlpine are credited for corporate work; Tom Dobleman and Patrick Loughery for finance; and Mike Carew and Adam Kool for tax.
